Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968551 | 0.94 | TLR7 (0.47) | TLR7ALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL3969352 | 0.92 | TLR7 (0.46) | TLR7ALDH1A1LMNATP53TLR8 | |
| SCHEMBL3968369 | 0.89 | TLR7 (0.58) | TLR7LMNASMN1; SMN2TP53TLR8 | |
| SCHEMBL3970939 | 0.84 | TLR7 (0.70) | TLR7TLR8 | |
| SCHEMBL3969529 | 0.83 | TLR7 (0.55) | TLR7LMNASMN1; SMN2TP53TLR8 | |
| SCHEMBL3975797 | 0.81 | TLR7 (0.53) | TLR7LMNASMN1; SMN2TP53TLR8 | |
| SCHEMBL5618745 | 0.81 | TLR7 (0.42) | TLR7LMNASMN1; SMN2TP53TLR8 | |
| SCHEMBL1950119 | 0.81 | GAA (0.47) | TLR7LMNASMN1; SMN2TP53HTT | |
| SCHEMBL3969176 | 0.81 | TLR7 (0.68) | TLR7ALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL5349914 | 0.80 | TLR7 (0.47) | TLR7LMNASMN1; SMN2TP53TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638566-A4 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7199131-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1638566-A2 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050197358-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-6924293-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-6888000-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| WO-2005003064-A2 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003065-A2 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-08 | — | — | US | disclosed |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-6677349-B1 | INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197358-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885ALDH1A1 1377/4885LMNA 4783/4885 |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885ALDH1A1 1377/4885LMNA 4783/4885 |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885ALDH1A1 1377/4885LMNA 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.